In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1+ or stronger labelling for CD-117 (up to a maximum of 4+). Three patients with neoplasms showing 4+ staining were selected for imatinib therapy. None responded. c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00008390-200508000-00008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunohistochemical Analysis of CD117 in the Mast Cells of Odontogenic Keratocysts.
Cureus
August 2024
Department of Oral Pathology and Microbiology, Government Dental College, Thrissur, Thrissur, IND.
Background: Odontogenic lesions contain mast cells (MCs), particularly those with a cystic appearance. Because of their high recurrence rates and aggressive clinical behaviour, odontogenic keratocysts (OKCs) require special treatment. A particular kind of protein called cluster of differentiation (CD) 117/ receptor tyrosine kinase (c-KIT) is present on the surface of many cells.
View Article and Find Full Text PDFDiagnostic Utility of EMA, Vimentin and CD117 Immunohistochemical Markers in Subtyping Renal Cell Carcinoma in a Nigerian Tertiary Hospital: A 10-year Retrospective Study.
West Afr J Med
October 2023
Department of Anatomic Pathology, Babcock University Teaching Hospital, Ilisan, Ogun State, Nigeria.
Background: Renal cell carcinoma is the most lethal urological cancer and contributes significantly to morbidity and mortality due to cancers of the urogenital tract. In routine diagnostic surgical pathology practice of renal tumours, immunohistochemistry is a helpful ancillary technique after routine H & E. The role of renal immunohistochemistry is explored in this study.
View Article and Find Full Text PDFA Rare Case of a Rectal Gastrointestinal Stromal Tumor (GIST) Discovered During a Routine Colonoscopy.
Cureus
June 2023
Gastroenterology, Desert Regional Medical Center, Palm Springs, USA.
A gastrointestinal stromal tumor (GIST) is a rare malignancy, accounting for only 0.1% to 3% of all gastrointestinal (GI) malignancies. Although GISTs are the most common mesenchymal tumor of the GI tract, they are primarily found within the stomach, with rectal GISTs rarely reported.
View Article and Find Full Text PDFRare Presentation of a Gastrointestinal Stromal Tumor Encapsulating the Spleen: A Case Report.
Cureus
April 2023
General Surgery, North Alabama Medical Center, Florence, USA.
Gastrointestinal stromal tumors (GISTs) are rare tumors of the digestive tract, often found incidentally on imaging. Although these tumors possess malignant potential, splenic encapsulation has not yet been described in the literature. A 74-year-old male fell and suffered blunt abdominal trauma followed by a 20-pound weight loss, early satiety, and left-sided abdominal pain.
View Article and Find Full Text PDFPrimary cutaneous adenoid cystic carcinoma of the scalp: dermatosurgical approach with favourable outcome.
Dermatol Reports
November 2022
Department of Pathology, University of Virginia, Charlottesville, USA.
Article Synopsis
- Primary cutaneous adenoid cystic carcinoma (PCACC) is a rare and complex skin cancer first identified in 1975, which can be easily mistaken for other skin tumors like melanoma and Merkel cell carcinoma.
- Diagnosing PCACC requires detailed examination using both standard tissue staining and special immunohistochemical markers.
- A case study of a 31-year-old patient shows successful surgical treatment of a scalp tumor, achieving good cosmetic results after complete resection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!